keyword
MENU ▼
Read by QxMD icon Read
search

aluminium adjuvant

keyword
https://www.readbyqxmd.com/read/28580849/-new-epicutaneous-method-for-the-causal-treatment-of-allergic-diseases
#1
László Endre
The only causal treatment for the allergic diseases is the allergen immunotherapy. Besides oral and injection forms, an epicutaneous form is known as well. During the immunization process the use of an adjuvant material is advisable besides the allergen. That adjuvant material can be (besides of the aluminium hydroxid and tyrosine) a bacterial toxin, too. In idealistic circumstances we can substitute the native allergen with its recombinant variant, which could keep its immunogenicity but had lost the allergenicity...
June 2017: Orvosi Hetilap
https://www.readbyqxmd.com/read/28576261/-critical-analysis-of-reference-studies-on-aluminium-based-adjuvants-toxicokinetics
#2
REVIEW
J-D Masson, G Crépeaux, F-J Authier, C Exley, R K Gherardi
We reviewed the three reference toxicokinetic studies commonly used to suggest innocuity of aluminum (Al)-based adjuvants. A single experimental study was carried out using isotopic (26)Al (Flarend et al., 1997). This study ignored adjuvant cell capture. It was conducted over a short period of time (28 days) and used only two rabbits per adjuvant. At the endpoint, Al retention was 78% for aluminum phosphate and 94% for aluminum hydroxide, both results being incompatible with quick elimination of vaccine-derived Al in urines...
May 30, 2017: Annales Pharmaceutiques Françaises
https://www.readbyqxmd.com/read/28542556/an-inactivated-hand-foot-and-mouth-disease-vaccine-using-the-enterovirus-71-c4a-strain-isolated-from-a-korean-patient-induces-a-strong-immunogenic-response-in-mice
#3
Hyun Ju In, Heeji Lim, Jung-Ah Lee, Hye Jin Kim, Jin-Won Kim, Ji-Yeon Hyeon, Sang-Gu Yeo, June-Woo Lee, Jung Sik Yoo, Young Ki Choi, Sang-Won Lee
Enterovirus 71 (EV71) is a major causative agent of hand-foot-and-mouth disease (HFMD) frequently occurring in children. HFMD induced by EV71 can cause serious health problems and has been reported worldwide, particularly in the Asia-Pacific region. In this study, we assessed the immunogenicity of a formalin-inactivated HFMD vaccine using an EV71 strain (FI-EV71 C4a) isolated from a Korean patient. The vaccine candidate was evaluated in mice to determine the vaccination doses and vaccine schedules. BALB/c mice were intramuscularly administered 5, 10, or 20 μg FI-EV71 vaccine, followed by a booster 2 weeks later...
2017: PloS One
https://www.readbyqxmd.com/read/28522427/association-of-chitosan-and-aluminium-as-a-new-adjuvant-strategy-for-improved-vaccination
#4
F Lebre, D Bento, J Ribeiro, M Colaço, G Borchard, M C Pedroso de Lima, O Borges
The use of particulate adjuvants offers an interesting possibility to enhance and modulate the immune responses elicited by vaccines. Aluminium salts have been extensively used as vaccine adjuvants, but they lack the capacity to induce a strong cellular and mucosal immune response. Taking this into consideration, in this study we designed a new antigen delivery system combining aluminium salts with chitosan. Chitosan-aluminium nanoparticles (CH-Al NPs) exhibited a mean diameter of 280nm and a positive surface charge...
May 15, 2017: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/28516859/recombinant-esterase-from-corynebacterium-pseudotuberculosis-in-dna-and-subunit-recombinant-vaccines-partially-protects-mice-against-challenge
#5
Alexandre Antunes Brum, Andrea de Fatima Silva Rezende, Francisco Silvestre Brilhante, Thais Collares, Karine Begnine, Fabiana Kommling Seixas, Tiago Veiras Collares, Odir Antônio Dellagostin, Vasco Azevedo, Anderson Santos, Ricardo Wagner Portela, Sibele Borsuk
PURPOSE: We tested the efficacy of the esterase encoded by cp1002_RS09720 from Corynebacteriumpseudotuberculosis in recombinant subunit and DNA caseous lymphadenitis (CLA) vaccines. This target was predicted as one of the best CLA vaccine candidates by mature epitope density analysis. METHODOLOGY: Gene cp1002_RS09720 was cloned into two different vectors (pAE for subunit vaccine and pTARGET for DNA vaccine). Four groups of 15 mice each were immunized with the recombinant esterase rCP09720 associated with aluminium hydroxide adjuvant (G1), pTARGET/cp09720 DNA vaccine (G2), a naked pTARGET (G3) or PBS as a negative control (G4)...
May 2017: Journal of Medical Microbiology
https://www.readbyqxmd.com/read/28456624/fusion-proteins-of-flagellin-and-the-major-birch-pollen-allergen-bet-v-1-show-enhanced-immunogenicity-reduced-allergenicity-and-intrinsic-adjuvanticity
#6
Claudia Kitzmüller, Julia Kalser, Sonja Mutschlechner, Michael Hauser, Gerhard J Zlabinger, Fatima Ferreira, Barbara Bohle
BACKGROUND: Recombinant fusion proteins of flagellin and antigens have been demonstrated to induce strong innate and adaptive immune responses. Such fusion proteins may enhance the efficacy of allergen-specific immunotherapy (AIT). OBJECTIVE: To characterize different fusion proteins of flagellin and the major birch pollen allergen Bet v 1 for suitability as allergy vaccines. METHODS: A truncated version of flagellin (NtCFlg) was genetically fused to the N- or C-terminus of Bet v 1...
April 26, 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28454674/immunogenicity-and-safety-of-three-aluminium-hydroxide-adjuvanted-vaccines-with-reduced-doses-of-inactivated-polio-vaccine-ipv-al-compared-with-standard-ipv-in-young-infants-in-the-dominican-republic-a-phase-2-non-inferiority-observer-blinded-randomised-and
#7
Luis Rivera, Rasmus S Pedersen, Lourdes Peña, Klaus J Olsen, Lars V Andreasen, Ingrid Kromann, Pernille I Nielsen, Charlotte Sørensen, Jes Dietrich, Ananda S Bandyopadhyay, Birgit Thierry-Carstensen
BACKGROUND: Cost and supply constraints are key challenges in the use of inactivated polio vaccine (IPV). Dose reduction through adsorption to aluminium hydroxide (Al) is a promising option, and establishing its effectiveness in the target population is a crucial milestone in developing IPV-Al. The aim of this clinical trial was to show the non-inferiority of three IPV-Al vaccines to standard IPV. METHODS: In this phase 2, non-inferiority, observer-blinded, randomised, controlled, single-centre trial in the Dominican Republic, healthy infants aged 6 weeks, not previously polio vaccinated, were allocated after computer-generated randomisation by block-size of four, to receive one of four IPV formulations (three-times reduced dose [1/3 IPV-Al], five-times reduced dose [1/5 IPV-Al], ten-times reduced dose [1/10 IPV-Al], or IPV) intramuscularly in the thigh at 6, 10, and 14 weeks of age...
April 25, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28378403/dose-sparing-and-lack-of-dose-response-relationship-with-an-influenza-vaccine-in-adult-and-elderly-patients-a-randomised-double-blind-clinical-trial
#8
Zoltan Vajo, Gergely Balaton, Peter Vajo, Laszlo Kalabay, Adam Erdman, Peter Torzsa
AIMS: The currently licensed seasonal trivalent influenza vaccines contain 15 micrograms of hemagglutinin per strain for adult, and up to 60 micrograms for elderly patients. However, due to recent shortages, dose sparing to increase production capacity would be highly desirable. In the present study, we attempted to find a dose-response relationship for immunogenicity and thus, the optimal dose for seasonal influenza vaccines in adult and elderly patients. METHODS: A total of 256 subjects, including adult (ages 18-60 years) and elderly (age over 60 years) were enrolled...
April 5, 2017: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28347293/comparison-of-a-novel-microcrystalline-tyrosine-adjuvant-with-aluminium-hydroxide-for-enhancing-vaccination-against-seasonal-influenza
#9
M D Heath, N J Swan, A C Marriott, N J Silman, B Hallis, C Prevosto, K E Gooch, M A Skinner
BACKGROUND: Vaccination against seasonal influenza strains is recommended for "high risk" patient groups such as infants, elderly and those with respiratory or circulatory diseases. However, efficacy of the trivalent influenza vaccine (TIV) is poor in many cases and in the event of an influenza pandemic, mono-valent vaccines have been rapidly developed and deployed. One of the main issues with use of vaccine in pandemic situations is the lack of a suitable quantity of vaccine early enough during the pandemic to exert a major influence on the transmission of virus and disease outcome...
March 27, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28319826/oil-based-adjuvants-delivered-intradermally-induce-high-primary-igg2-immune-response-in-swine
#10
Zrinka Oreskovic, Hana Kudlackova, Josef Krejci, Katerina Nechvatalova, Martin Faldyna
The effects of intradermal application of antigen with or without different adjuvants and activation of immune response are presented in this study. Six groups of six piglets each were immunized with keyhole limpet haemocyanin (KLH) antigen in combination with aluminium hydroxide or oil-based adjuvants (complete and incomplete Freund's adjuvants, Montanide ISA 206 and Emulsigen). IgG1 and IgG2 levels in sera were measured by KLH-specific ELISA. Interestingly, oil-based adjuvants induced high primary IgG2 response, suggesting the Th1 lymphocyte polarization...
March 11, 2017: Research in Veterinary Science
https://www.readbyqxmd.com/read/28302762/brain-fdg-pet-metabolic-abnormalities-in-macrophagic-myofasciitis-are-they-stable
#11
Paul Blanc-Durand, Axel Van Der Gucht, Mehdi Aoun Sebaiti, Mukedaisi Abulizi, Francois-Jérome Authier, Emmanuel Itti
We address this letter in addition to our recent published study (1). The aim is to add some insight to the evolution of the brain abnormalities that are observed with macrophagic myofasciitis (MMF). MMF is a chronic disease whom evolution is slow and symptoms first may occurs from months to year after a vaccination containing aluminium hydroxid adjuvants (2). Nevertheless, its evolution is not fully understood or known. MMF associated cognitive dysfunction (MACD) is based on a tripod combining dysexecutive syndrom, visual memory impairment and interhemispheric disconnection...
March 16, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28237896/towards-toxicokinetic-modelling-of-aluminium-exposure-from-adjuvants-in-medicinal-products
#12
Karin Weisser, Sabine Stübler, Walter Matheis, Wilhelm Huisinga
As a potentially toxic agent on nervous system and bone, the safety of aluminium exposure from adjuvants in vaccines and subcutaneous immune therapy (SCIT) products has to be continuously re-evaluated, especially regarding concomitant administrations. For this purpose, knowledge on absorption and disposition of aluminium in plasma and tissues is essential. Pharmacokinetic data after vaccination in humans, however, are not available, and for methodological and ethical reasons difficult to obtain. To overcome these limitations, we discuss the possibility of an in vitro-in silico approach combining a toxicokinetic model for aluminium disposition with biorelevant kinetic absorption parameters from adjuvants...
February 22, 2017: Regulatory Toxicology and Pharmacology: RTP
https://www.readbyqxmd.com/read/28183282/enhanced-and-long-term-immunogenicity-of-a-her-2-neu-multi-epitope-vaccine-conjugated-to-the-carrier-crm197-in-conjunction-with-the-adjuvant-montanide
#13
Joshua Tobias, Joanna Jasinska, Karin Baier, Michael Kundi, Nicholas Ede, Christoph Zielinski, Ursula Wiedermann
BACKGROUND: We previously identified three short single peptides (P4, P6 and P7) representing different B-cell epitopes on the extracellular domain of Her-2/neu for a vaccine that was tested in a phase-I clinical trial. Here we describe the improvement of the multi peptide vaccine by fusing the single peptides to a hybrid peptide P467. METHODS: After coupling to either virosomes or to diphtheria toxoid CRM197 (CRM), the hybrid peptide was tested in different concentrations in combination with either Montanide or Aluminium hydroxide (Alum) in preclinical studies...
February 9, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28027810/first-in-human-safety-and-immunogenicity-investigations-of-three-adjuvanted-reduced-dose-inactivated-poliovirus-vaccines-ipv-al-ssi-compared-to-full-dose-ipv-vaccine-ssi-when-given-as-a-booster-vaccination-to-adolescents-with-a-history-of-ipv-vaccination-at
#14
Line M Lindgren, Pernille N Tingskov, Annette H Justesen, Bettina S Nedergaard, Klaus J Olsen, Lars V Andreasen, Ingrid Kromann, Charlotte Sørensen, Jes Dietrich, Birgit Thierry-Carstensen
BACKGROUND: There is a demand of affordable IPV in the World. Statens Serum Institut (SSI) has developed three reduced dose IPV formulations adsorbed to aluminium hydroxide; 1/3 IPV-Al, 1/5 IPV-Al and 1/10 IPV-Al SSI, and now report the results of the first investigations in humans. METHODS: 240 Danish adolescents, aged 10-15years, and childhood vaccinated with IPV were booster vaccinated with 1/3 IPV-Al, 1/5 IPV-Al, 1/10 IPV-Al or IPV Vaccine SSI. The booster effects (GMTRs) of the three IPV-Al SSI were compared to IPV Vaccine SSI, and evaluated for non-inferiority...
January 23, 2017: Vaccine
https://www.readbyqxmd.com/read/27941323/immunogenicity-and-safety-of-pandemic-influenza-h5n1-vaccines-in-healthy-adults-through-meta-analysis
#15
Qi Guo, Ze Liu, Jingxia Gao, Jian Zhou, Wenzhu Hu, Yina Cun, Weidong Li, Guoyang Liao
BACKGROUND: There are sporadic cases and local outbreaks of H5N1 avian influenza virus worldwide every year. The World Health Organization (WHO) has paid close attention to the avian influenza epidemic trend. Avian influenza vaccines (AIV) are considered to be useful when an epidemic occurs. However, the use of AIV for humans is not yet widespread. METHODS: This study assessed the immunogenicity and safety of pandemic influenza H5N1 vaccines with inactivated whole virus, split virus and subunit virus vaccines for healthy adults...
2016: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/27913028/active-immunization-with-brucella-abortus-s19-phage-lysate-elicits-serum-igg-that-protects-guinea-pigs-against-virulent-b-%C3%A2-abortus-and-protects-mice-by-passive-immunization
#16
Lata Jain, Mayank Rawat, Saravanan Ramakrishnan, Bablu Kumar
Brucellosis is an economically important zoonosis of worldwide significance. Earlier (Jain et al., 2015) we reported methodology for generation of phage lysate preparations against Brucella abortus S19 using brucellaphage 'ϕLd'. In this study, using a fixed dose (Two mouse PD100) of lysates, the prophylactic efficacies of both plain and alum gel adjuvanted lysates were evaluated in guinea pig by direct virulent challenge and passive mouse protection test (PMPT). Strong humoral and cell mediated immune responses in guinea pigs and protection comparable to S19 vaccine was observed with low dose (1...
January 2017: Biologicals: Journal of the International Association of Biological Standardization
https://www.readbyqxmd.com/read/27908630/non-linear-dose-response-of-aluminium-hydroxide-adjuvant-particles-selective-low-dose-neurotoxicity
#17
Guillemette Crépeaux, Housam Eidi, Marie-Odile David, Yasmine Baba-Amer, Eleni Tzavara, Bruno Giros, François-Jérôme Authier, Christopher Exley, Christopher A Shaw, Josette Cadusseau, Romain K Gherardi
Aluminium (Al) oxyhydroxide (Alhydrogel(®)), the main adjuvant licensed for human and animal vaccines, consists of primary nanoparticles that spontaneously agglomerate. Concerns about its safety emerged following recognition of its unexpectedly long-lasting biopersistence within immune cells in some individuals, and reports of chronic fatigue syndrome, cognitive dysfunction, myalgia, dysautonomia and autoimmune/inflammatory features temporally linked to multiple Al-containing vaccine administrations. Mouse experiments have documented its capture and slow transportation by monocyte-lineage cells from the injected muscle to lymphoid organs and eventually the brain...
January 15, 2017: Toxicology
https://www.readbyqxmd.com/read/27845595/cna-loaded-plga-nanoparticles-improve-humoral-response-againsts-aureus-mediated-infections-in-a-mouse-model-subcutaneous-vs-nasal-administration-strategy
#18
Ida Genta, Claudia Colonna, Bice Conti, Paolo Caliceti, Stefano Salmaso, Pietro Speziale, Giampiero Pietrocola, Enrica Chiesa, Tiziana Modena, Rossella Dorati
The aim of this work was the assessment of the "in vivo" immune response of a poly(lactide-co-glycolide)-based nanoparticulate adjuvant for a sub-unit vaccine, namely, a purified recombinant collagen-binding bacterial adhesion fragment (CNA19), against Staphylococcus aureus-mediated infections. "In vivo" immunogenicity studies were performed on mice: immunisation protocols encompassed subcutaneous and intranasal administration of CNA19 formulated as nanoparticles (NPs) and furthermore, CNA19-loaded NPs formulated in a set-up thermosetting chitosan-β-glycerolphosphate (chitosan-β-GP) solution for intranasal route in order to extend antigen exposure to nasal mucosa...
December 2016: Journal of Microencapsulation
https://www.readbyqxmd.com/read/27651089/immune-responses-of-a-meningococcal-a-w-outer-membrane-vesicle-omv-vaccine-with-and-without-aluminium-hydroxide-adjuvant-in-two-different-mouse-strains
#19
Gro Tunheim, Marianne Arnemo, Lisbeth M Naess, Gunnstein Norheim, Luis Garcia, Daniel Cardoso, Aleida Mandiarote, Domingo Gonzalez, Kalpana Sinnadurai, Åse-Karine Fjeldheim, Karin Bolstad, Einar Rosenqvist
Meningococci (Neisseria meningiditis) of serogroups A and W have caused large epidemics of meningitis in sub-Saharan Africa for decades, and affordable and multivalent vaccines, effective in all age groups, are needed. A bivalent serogroup A and W (A + W) meningococcal vaccine candidate consisting of deoxycholate-extracted outer membrane vesicles (OMV) from representative African disease isolates was previously found to be highly immunogenic in outbred mice when formulated with the adjuvant aluminium hydroxide (AH)...
November 2016: APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica
https://www.readbyqxmd.com/read/27551808/vaccine-adjuvants-why-and-how
#20
Dennis Christensen
Novel vaccine strategies include the so-called subunit vaccines, which encompass only the part of the pathogen to which immune recognition results in protection. The high purity of these vaccines make adverse events less likely, but it also makes the vaccines less immunogenic and therefore potentially less effective. Vaccine adjuvants that increase and modulate the immunogenicity of the vaccine are therefore added to solve this problem. Besides aluminum salts, which have been used in vaccines for 90 years, a number of novel vaccine adjuvants have been included in licensed vaccines over the last 30 years...
October 2, 2016: Human Vaccines & Immunotherapeutics
keyword
keyword
110660
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"